Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
J Neuroimmunol ; 110(1-2): 57-65, 2000 Oct 02.
Artigo em Inglês | MEDLINE | ID: mdl-11024534

RESUMO

beta-Adrenoceptor (betaAR) expression and function as well as its modulation via intracellular transduction signals, were analyzed on the T cell lymphoma BW5147. Independently to the kinetic of proliferation and relative to the number of receptors displayed in normal T lymphocytes, BW5147 cells displayed a decreased number of betaAR, uncoupled to adenylate cyclase, but coupled to protein kinase C stimulation. This last effect was impaired by a beta-antagonist and by blockers of the enzymatic pathways involved in T lymphocyte proliferation, inducing a recovery of betaAR sites. Down-regulation of betaAR would implicate the loss of a negative neuroimmune control mechanism for lymphocyte proliferation. The coupling of the remaining sites to a positive signal for cellular activation, would contribute to establish an hyperproliferative state.


Assuntos
Proteína Quinase C/metabolismo , Receptores Adrenérgicos beta/metabolismo , Linfócitos T/citologia , Linfócitos T/enzimologia , 1-(5-Isoquinolinasulfonil)-2-Metilpiperazina/farmacologia , Adenilil Ciclases/metabolismo , Agonistas Adrenérgicos beta/farmacologia , Divisão Celular/efeitos dos fármacos , Divisão Celular/imunologia , Ativação Enzimática/imunologia , Inibidores Enzimáticos/farmacologia , Humanos , Indóis/farmacologia , Isoproterenol/farmacologia , Linfoma de Células T , Maleimidas/farmacologia , Neuroimunomodulação/imunologia , Proteína Quinase C/antagonistas & inibidores , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/imunologia , Linfócitos T/imunologia , Células Tumorais Cultivadas
2.
Cell Mol Neurobiol ; 20(3): 255-68, 2000 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-10789827

RESUMO

1. The aim of the present work was to determine hypoxia-induced modifications in the cascade of intracellular events coupled to muscarinic acetylcholine receptor (mAChR) activation in brain. For this purpose, enzymatic activities were measured on normoxically incubated frontal cortical slices from mice exposed to hypobaric hypoxia for 72 hr. 2. We found that hypoxia induced alterations in several cerebral enzymatic basal activities: it increased nitric oxide synthase (NOS), but it decreased both membrane protein kinase C (PKC) and phospholipase C activities. 3. The mAChR agonist carbachol was found to increase phosphoinositide hydrolysis to greater values in hypoxic tissues than those found in normoxic conditions. Furthermore, a greater translocation of PKC in response to carbachol was observed in hypoxic tissues than in normoxic ones. 4. Besides, carbachol induced a drastic reduction of NOS activity in hypoxic brains, at concentrations that stimulated this enzyme activity in normoxic preparations. In the latter, inhibition is obtained only with high concentrations of the cholinergic muscarinic agonist. 5. These results pointed to a carbachol-mediated mAChR hyperactivity induced by hypoxic insult. 6. The possibility that these effects would account for a compensatory mechanism to diminish NOS hyperactivity, probably protecting for NO neurotoxic action in hypoxic brain, is also discussed.


Assuntos
Lobo Frontal/fisiologia , Hipóxia Encefálica/fisiopatologia , Fenilcarbamatos , Receptores Muscarínicos/fisiologia , Transdução de Sinais/fisiologia , Pressão do Ar , Animais , Atropina/farmacologia , Carbacol/farmacologia , Carbamatos/farmacologia , Quelantes/farmacologia , Agonistas Colinérgicos/farmacologia , Ácido Egtázico/análogos & derivados , Ácido Egtázico/farmacologia , Inibidores Enzimáticos/farmacologia , Lobo Frontal/citologia , Camundongos , Camundongos Endogâmicos , Antagonistas Muscarínicos/farmacologia , Neurônios/química , Neurônios/efeitos dos fármacos , Neurônios/enzimologia , Óxido Nítrico Sintase/metabolismo , Óxido Nítrico Sintase Tipo I , Fosfatidilinositóis/metabolismo , Inibidores de Fosfodiesterase/farmacologia , Proteína Quinase C/metabolismo , Receptor Cross-Talk/fisiologia , ômega-N-Metilarginina/farmacologia
3.
Can J Physiol Pharmacol ; 77(1): 22-8, 1999 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-10535662

RESUMO

In addition to its effect on D2 dopamine receptor blockades, haloperidol is able to interact with multiple neurotransmitters (NTs). Its action on phosphoinositide (PI) turnover was studied on cerebral cortex preparations. It induces an increase in inositol phosphate (IP) accumulation, which was only blunted by the alpha1-adrenoceptor blocker prazosin. Haloperidol maximal effect (Emax) was less than the effect of the full agonist norepinephrine (NE), and dose-response curves for both NE in the presence of submaximal doses of haloperidol and haloperidol in the presence of Emax doses of NE showed that haloperidol behaves as a partial agonist of cerebral alpha1-adrenoceptors. Its effect on PI hydrolysis is mediated through phospholipase C activation, as 2-nitro-4-carboxyphenyl-N,N-diphenylcarbamate (NCDC) and 1-[6-([(17beta)-3-methoxyestra- 1,3,5(10)-trien-17-yl]amino)hexyl]-1H-pyrrole-2,5-dione) (U-73122) were able to abrogate both haloperidol and NE actions. Further, the typical neuroleptic exerts a direct activation of alpha1-adrenoceptors as its actions were not modified by cocaine and persisted in spite of chemical rat cerebral denervation with 6-hydroxydopamine (6-OHDA). The possibility that this agonistic action on alpha1-adrenoceptors would be involved in haloperidol side effects is also discussed.


Assuntos
Antipsicóticos/farmacologia , Lobo Frontal/efeitos dos fármacos , Haloperidol/farmacologia , Fosfatidilinositóis/metabolismo , Receptores Adrenérgicos alfa 1/efeitos dos fármacos , Animais , Relação Dose-Resposta a Droga , Feminino , Hidrólise , Norepinefrina/farmacologia , Ratos , Ratos Wistar , Fosfolipases Tipo C/metabolismo
4.
Cell Signal ; 11(4): 293-300, 1999 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-10372807

RESUMO

The induction of intracellular signals coupled to alpha1-adrenoceptor by haloperidol, were studied in rat cerebral frontal cortex. The neuroleptic exerts a biphasic effect on nitric oxide synthase (NOS), inhibiting the enzymatic activity at low concentrations (10(-9) M), while higher concentrations (10(-5) M) increased it. Protein kinase C (PKC) and phosphoinositol turnover (PIs) were involved in these actions, as haloperidol induced PKC translocation at low concentrations, and increased PIs turnover at high concentrations. All the effects of haloperidol were blocked by the alpha-adrenoceptor antagonist prazosin and the phospholipase C (PLC) inhibitor NCDC. The possibility that a cross-talk between both enzymatic pathways depending on the neuroleptic concentration used in rat cerebral frontal cortex, is also discussed.


Assuntos
Agonistas de Receptores Adrenérgicos alfa 1 , Lobo Frontal/metabolismo , Haloperidol/farmacologia , Transdução de Sinais , Antagonistas de Receptores Adrenérgicos alfa 1 , Animais , Técnicas de Cultura , Lobo Frontal/efeitos dos fármacos , Fosfatos de Inositol/metabolismo , Líquido Intracelular/metabolismo , Óxido Nítrico Sintase/metabolismo , Óxido Nítrico Sintase Tipo I , Proteína Quinase C/metabolismo , Ratos
5.
Synapse ; 31(2): 151-3, 1999 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-10024012

RESUMO

Previously, we demonstrated that gamma vinyl-GABA (GVG, Vigabatrin) dose-dependently inhibits cocaine-induced increases in dopamine (DA) concentrations in both the rodent and primate brain. Furthermore, it abolishes cocaine self-administration and conditioned place preference, while having no effect on locomotor activity or drug delivery to the brain. In an effort to better understand the mechanisms underlying this inhibition, we examined the effect of the selective GABA(B) receptor antagonist SCH 50911 on the GVG-induced decrease in cocaine's elevation of extracellular DA concentrations in the nucleus accumbens (NACC). Cocaine administration alone (20 mg/kg i.p.) produced a 480% increase in extracellular NACC DA levels. GVG (300 mg/kg i.p.) significantly reduced this increase by 25% (P<0.01). In sharp contrast, extracellular DA levels increased to 550% after the sequential administration of SCH 50911 (3 mg/kg i.p.), GVG, and cocaine. This increase is significantly different than GVG and cocaine (P<0.05) but similar to cocaine alone. These results demonstrate that the GABA(B) antagonist SCH 50911 was able to completely abolish GVG's inhibition of cocaine-induced increases in DA in the NACC and implicates the GABA(B) receptor in the mechanism underlying this inhibition.


Assuntos
Cocaína/farmacologia , Inibidores da Captação de Dopamina/farmacologia , Dopamina/metabolismo , Inibidores Enzimáticos/farmacologia , Núcleo Accumbens/efeitos dos fármacos , Receptores de GABA-B/efeitos dos fármacos , Ácido gama-Aminobutírico/análogos & derivados , Animais , Antagonistas GABAérgicos/farmacologia , Masculino , Morfolinas/farmacologia , Núcleo Accumbens/metabolismo , Ratos , Ratos Sprague-Dawley , Receptores de GABA-B/metabolismo , Vigabatrina , Ácido gama-Aminobutírico/farmacologia
6.
J Neural Transm (Vienna) ; 105(2-3): 193-204, 1998.
Artigo em Inglês | MEDLINE | ID: mdl-9660097

RESUMO

Biochemical signalling events coupled to muscarinic cholinergic receptors (mAChR), specifically those related to nitric oxide (NO) production, were studied on rat cerebral frontal cortex. The mAChR agonist carbachol was found to exert a specific biphasic action on NO synthase (NOS) activity: low doses ranging between 10(-9) M to 10(-7) M lead to NOS activation while higher doses (>10(-6) M) inhibited enzymatic activity. Carbachol stimulatory action was blunted by agents that interfere with calcium-calmodulin while a protein kinase (PKC) inhibitor, staurosporine was able to abrogate the inhibitory effect. Moreover, PKC activity showed maximum translocation to cerebral frontal cortex membranes with carbachol concentrations that inhibited NO production. Products from phosphoinosite (PI) hydrolysis are involved in these actions as carbachol was found to increase PI turnover in a dose dependent manner. These results would serve as an example of cross-talk between both enzymatic pathways.


Assuntos
Química Encefálica/fisiologia , Óxido Nítrico/fisiologia , Receptores Muscarínicos/metabolismo , Transdução de Sinais/fisiologia , Animais , Carbacol/farmacologia , Relação Dose-Resposta a Droga , Ativação Enzimática/efeitos dos fármacos , Técnicas In Vitro , Fosfatos de Inositol/metabolismo , Agonistas Muscarínicos/farmacologia , Óxido Nítrico Sintase/metabolismo , Óxido Nítrico Sintase Tipo I , Córtex Pré-Frontal/efeitos dos fármacos , Córtex Pré-Frontal/enzimologia , Proteína Quinase C/antagonistas & inibidores , Proteína Quinase C/metabolismo , Ratos
7.
Artigo em Inglês | MEDLINE | ID: mdl-9339247

RESUMO

As several side effects of neuroleptics would be related to their interactions with several neurotransmitter receptors (R) haloperidol action on muscarinic cholinergic (mACh) R on frontal cerebral cortex preparations was analyzed. Here we show that haloperidol was able to inhibit in a concentration dependent manner the binding of specific mAChR radiolabeled antagonist on cerebral cortex membranes. This effect would be related to its interaction on mAChR of the M1 subtype as haloperidol blocked the stimulation of phosphoinositides (PIs) turnover induced by low concentrations of carbachol similarly as the M1 antagonist pirenzepine. However at high carbachol concentrations haloperidol triggered a potentiating stimulation of PIs hydrolysis that was only blocked by the alpha 1 adrenergic antagonist prazosin indicating an alpha 1 agonistic action of haloperidol on these Rs. These multireceptor actions of haloperidol found "in vitro" would strengthen its association with "in vivo" neuroleptic-induced side effects.


Assuntos
Antipsicóticos/farmacologia , Córtex Cerebral/efeitos dos fármacos , Haloperidol/farmacologia , Antagonistas Muscarínicos , Receptores Muscarínicos/efeitos dos fármacos , Animais , Sítios de Ligação , Carbacol , Técnicas In Vitro , Fosfatos de Inositol , Agonistas Muscarínicos , Quinuclidinil Benzilato , Ratos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA